Leerink Partnrs Predicts Biogen's Q3 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB - Free Report) - Research analysts at Leerink Partnrs boosted their Q3 2025 earnings per share estimates for Biogen in a research note issued to investors on Thursday, May 1st. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will post earnings per share of $4.14 for the quarter, up from their previous estimate of $3.96. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Leerink Partnrs also issued estimates for Biogen's FY2026 earnings at $15.95 EPS and FY2029 earnings at $19.00 EPS.

Other equities analysts have also issued research reports about the stock. Morgan Stanley dropped their price target on shares of Biogen from $157.00 to $152.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. Scotiabank reduced their price objective on Biogen from $244.00 to $224.00 and set a "sector outperform" rating on the stock in a research note on Thursday, February 13th. JPMorgan Chase & Co. reduced their price target on shares of Biogen from $185.00 to $175.00 and set a "neutral" rating on the stock in a research report on Monday. William Blair reiterated an "outperform" rating on shares of Biogen in a research note on Monday, January 13th. Finally, Oppenheimer set a $205.00 price objective on Biogen in a report on Friday. Twenty equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $192.70.

Biogen Trading Down 4.0 %

Shares of NASDAQ BIIB traded down $4.89 on Monday, reaching $116.92. 1,735,727 shares of the company traded hands, compared to its average volume of 1,357,359. The stock has a market capitalization of $17.11 billion, a PE ratio of 10.45, a P/E/G ratio of 1.51 and a beta of 0.13. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. The company has a 50 day moving average of $130.21 and a 200 day moving average of $145.97.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.26 by ($0.24). Biogen had a return on equity of 14.98% and a net margin of 16.87%. The firm had revenue of $2.43 billion for the quarter, compared to analyst estimates of $2.25 billion. During the same period in the prior year, the business earned $3.67 earnings per share. Biogen's revenue for the quarter was up 6.2% on a year-over-year basis.

Insiders Place Their Bets

In related news, Director Stephen A. Sherwin sold 8,760 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the transaction, the director now directly owns 11,318 shares in the company, valued at $1,697,926.36. This represents a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BIIB. World Investment Advisors LLC acquired a new stake in shares of Biogen in the 3rd quarter valued at approximately $1,118,000. Wilmington Savings Fund Society FSB acquired a new stake in Biogen in the third quarter worth $150,000. Tidal Investments LLC boosted its position in shares of Biogen by 13.6% during the third quarter. Tidal Investments LLC now owns 9,012 shares of the biotechnology company's stock worth $1,747,000 after purchasing an additional 1,082 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Biogen by 3.2% in the 3rd quarter. Principal Financial Group Inc. now owns 168,631 shares of the biotechnology company's stock valued at $32,687,000 after buying an additional 5,270 shares in the last quarter. Finally, Versant Capital Management Inc raised its stake in Biogen by 228.7% during the 4th quarter. Versant Capital Management Inc now owns 401 shares of the biotechnology company's stock worth $61,000 after buying an additional 279 shares during the period. 87.93% of the stock is currently owned by institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.